# Silybum eburneum

**Canonical URL:** https://ingredients.hermeticasuperfoods.com/ingredients/silybum-eburneum
**Data Source:** Hermetica Superfoods Ingredient Encyclopedia
**Updated:** 2026-04-02
**Evidence Score:** 2 / 10
**Category:** Other
**Also Known As:** Silybum eburneum Coss. & Dur., White-stemmed milk thistle, North African milk thistle, Tunisian milk thistle, Mediterranean silybum, White milk thistle

## Overview

Silybum eburneum is a thistle plant whose seeds contain flavonolignan compounds, most notably silybin-related constituents, that exert antioxidant effects by scavenging [reactive oxygen species](/ingredients/condition/antioxidant) and protecting cellular membranes from lipid peroxidation. Research is in early stages, but in vitro evidence suggests activity comparable to established antioxidants like α-tocopherol.

## Health Benefits

• [Antioxidant](/ingredients/condition/antioxidant) cell protection: In vitro studies show S. eburneum seed extracts protect cells from oxidative damage at 100 μg/mL, comparable to α-tocopherol (preliminary evidence)
• Potential blood sugar support: Related S. marianum showed significant HbA1c and fasting glucose reductions in RCT (n=51) at 600 mg/day (evidence extrapolated)
• Possible liver enzyme improvement: S. marianum trials demonstrated reduced SGOT and SGPT levels in diabetes patients (evidence extrapolated)
• [Cardiovascular](/ingredients/condition/heart-health) markers: S. marianum studies showed improvements in total cholesterol, LDL, and triglycerides (evidence extrapolated)
• High isosilychristin content: Contains up to 19.5 mg/g DW (61.53% of total silymarin), potentially supporting multidrug resistance modulation (preliminary evidence)

## Mechanism of Action

Flavonolignan constituents in S. eburneum seed extracts are believed to neutralize [reactive oxygen species](/ingredients/condition/antioxidant) by donating hydrogen atoms to free radicals, thereby interrupting lipid peroxidation chain reactions in cell membranes. These compounds may also modulate [glucose metabolism](/ingredients/condition/weight-management) pathways by influencing insulin signaling and GLUT4 transporter expression, as extrapolated from closely related S. marianum research involving silybin interaction with peroxisome proliferator-activated receptors (PPARs). Additionally, flavonolignans may inhibit NF-κB activation, reducing downstream [inflammatory](/ingredients/condition/inflammation) cytokine production that contributes to oxidative cellular damage.

## Clinical Summary

Direct clinical trials on Silybum eburneum in humans are currently absent from the published literature, making evidence assessment reliant on in vitro and species-extrapolation data. In vitro studies demonstrate that S. eburneum seed extracts at 100 μg/mL provide cell protection from oxidative damage comparable to α-tocopherol, though cell culture findings do not reliably predict human outcomes. A randomized controlled trial (n=51) on the closely related species S. marianum reported statistically significant reductions in HbA1c and fasting [blood glucose](/ingredients/condition/weight-management), but these findings cannot be directly attributed to S. eburneum without species-specific trials. Overall, the evidence base is preliminary and requires human clinical studies before therapeutic claims can be substantiated.

## Nutritional Profile

Silybum eburneum (ivory milk thistle) seed composition is incompletely characterized, but extrapolation from the closely related S. marianum and available phytochemical studies provides the following framework: Primary bioactive compounds include silymarin-complex flavonolignans (silibinin, silidianin, silicristin, isosilybin) estimated at 1–3% of seed dry weight, lower than S. marianum's typical 1.5–3% but structurally analogous. Seed oil content is approximately 20–30% of dry weight, dominated by linoleic acid (omega-6, ~55–60% of fatty acids) and oleic acid (~25–30%), with minor palmitic and stearic acid fractions. Crude protein content in thistle seeds generally ranges 15–25% dry weight. Fiber content (hull-inclusive) is estimated at 20–30% dry weight, with insoluble fiber predominating. Polyphenol content in seed extracts has been measured at approximately 12–18 mg gallic acid equivalents per gram of extract in preliminary in vitro work. Taxifolin (a dihydroflavonol precursor to silymarin) is likely present at trace levels. Mineral content is expected to include magnesium (~200–350 mg/100g seed), potassium (~400–600 mg/100g), phosphorus (~500–700 mg/100g), and iron (~5–10 mg/100g), based on Asteraceae seed family data. Vitamin E (tocopherols, particularly γ-tocopherol) is present in seed oil at an estimated 40–80 mg/100g oil. Bioavailability note: Silymarin-type flavonolignans have low oral bioavailability (~20–50%) due to poor aqueous solubility; phospholipid complexation or nanoparticle formulations improve absorption. Data on S. eburneum specifically remains limited to in vitro seed extract studies at 100 μg/mL concentrations; full macro/micronutrient profiling via HPLC and proximate analysis has not been published in peer-reviewed literature as of early 2025.

## Dosage & Preparation

No clinically studied dosages exist for S. eburneum specifically. Related S. marianum silymarin trials used 420-600 mg/day (140-200 mg three times daily) of standardized extract (70-80% silymarin) for 45 days to 4 months. Higher doses up to 2.1-4.5 g/day were well-tolerated in other studies. Consult a healthcare provider before starting any new supplement.

## Safety & Drug Interactions

No human safety trials specific to Silybum eburneum have been published, so safety inferences are drawn from its botanical relative S. marianum, which is generally well tolerated with occasional mild gastrointestinal side effects such as bloating, nausea, and loose stools. Flavonolignan compounds in related species can inhibit cytochrome P450 enzymes (CYP3A4, CYP2C9), potentially elevating plasma concentrations of co-administered drugs including statins, anticoagulants like warfarin, and certain antiretrovirals. S. eburneum is contraindicated in individuals with known allergies to Asteraceae/Compositae family plants, including ragweed, chrysanthemums, and daisies. Pregnant or breastfeeding individuals should avoid use due to the complete absence of reproductive safety data for this specific species.

## Scientific Research

No human clinical trials exist specifically for Silybum eburneum; evidence is extrapolated from its close relative S. marianum. Key S. marianum trials include a 4-month RCT (n=51, PMID: 17072885) showing significant metabolic improvements with 600 mg/day, and a 45-day RCT (n=40) demonstrating enhanced [antioxidant](/ingredients/condition/antioxidant) indices with 420 mg/day. A review (PMID: 17548793) noted silymarin's potential in liver disease, diabetes, and hypercholesterolemia.

## Historical & Cultural Context

Silybum eburneum lacks documented historical traditional use, unlike its relative S. marianum which has been used for nearly 2000 years in European traditional medicine for liver protection. S. eburneum is noted only in modern Tunisian contexts as a potential nutrient and [antioxidant](/ingredients/condition/antioxidant) source, with no established traditional medicinal history.

## Synergistic Combinations

Alpha-tocopherol, N-acetylcysteine, Selenium, Vitamin C, Curcumin

## Frequently Asked Questions

### What is Silybum eburneum and how does it differ from milk thistle?

Silybum eburneum is a wild thistle species closely related to the well-studied Silybum marianum (milk thistle), sharing a similar flavonolignan-rich seed composition but representing a distinct botanical species with its own phytochemical profile. While S. marianum has decades of clinical research behind it, S. eburneum remains largely unstudied in humans, meaning its potency, optimal dosing, and therapeutic applications have not been independently established. Researchers use S. marianum data as a preliminary reference point, but direct comparison studies between the two species do not yet exist.

### Can Silybum eburneum help lower blood sugar levels?

There is no direct human clinical evidence that Silybum eburneum lowers blood sugar; the association comes from a related species, S. marianum, which in a 45-day RCT (n=51) produced significant reductions in HbA1c and fasting glucose in type 2 diabetic patients. The proposed mechanism involves silybin-type flavonolignans modulating PPAR-γ activity and improving insulin sensitivity at the cellular level. Until species-specific trials are conducted for S. eburneum, any blood sugar benefit remains speculative and it should not replace prescribed antidiabetic medications.

### What antioxidant compounds are found in Silybum eburneum seeds?

Silybum eburneum seeds contain flavonolignan compounds structurally similar to silybin, isosilybin, silydianin, and silychristin found in S. marianum, though the exact quantitative profile for S. eburneum has not been fully characterized in published research. In vitro assays at 100 μg/mL of seed extract demonstrated cell-protective antioxidant activity equivalent to α-tocopherol (Vitamin E), suggesting meaningful radical-scavenging capacity. These flavonolignans are believed to act primarily by interrupting lipid peroxidation cascades and chelating pro-oxidant metal ions such as iron and copper.

### Is there a recommended dosage for Silybum eburneum supplements?

No clinically validated dosage has been established for Silybum eburneum because human pharmacokinetic and dose-finding studies have not been conducted for this species. By comparison, standardized S. marianum extracts (70–80% silymarin) are commonly used in research at 140–420 mg per day divided into two or three doses. Any S. eburneum supplement dosage is currently manufacturer-determined and not evidence-based, so consumers should approach such products with caution and consult a healthcare provider before use.

### Does Silybum eburneum interact with any medications?

Based on mechanisms observed with the closely related S. marianum, S. eburneum flavonolignans may inhibit hepatic cytochrome P450 enzymes, particularly CYP3A4 and CYP2C9, which are responsible for metabolizing a wide range of drugs including warfarin, cyclosporine, statins, and certain HIV protease inhibitors. Inhibition of these enzymes could raise plasma drug concentrations to potentially toxic levels or prolong their effects unpredictably. Individuals taking any prescription medications, especially anticoagulants or immunosuppressants, should consult their physician before using S. eburneum products, as species-specific interaction data are unavailable.

### What is the most bioavailable form of Silybum eburneum supplement?

Silybum eburneum seed extracts standardized to silymarin content typically offer higher bioavailability compared to whole seed powder, as the active compounds are concentrated and more readily absorbed. Lipophilic formulations and phytosome complexes may further enhance absorption, though direct comparative bioavailability studies specific to S. eburneum are limited. The extraction method and standardization percentage significantly influence how much of the active constituents your body can utilize.

### Who should avoid taking Silybum eburneum supplements?

Individuals with known allergies to plants in the Asteraceae family (ragweed, chrysanthemums, dahlias) should exercise caution due to potential cross-reactivity. Pregnant and nursing women should consult healthcare providers before use, as safety data in these populations is insufficient. Those taking immunosuppressant medications or with estrogen-sensitive conditions should discuss S. eburneum use with their doctor, as silymarin may have mild estrogenic activity.

### How strong is the clinical evidence supporting Silybum eburneum for health benefits?

Evidence for S. eburneum is primarily preliminary, based on in vitro studies demonstrating antioxidant cell protection at 100 μg/mL and extrapolated data from related species (S. marianum) showing blood sugar improvements in human trials. While S. marianum has more robust clinical research, direct human clinical trials specifically on S. eburneum remain limited, making it difficult to make definitive health claims for this species. Most available evidence is categorized as preliminary or supporting rather than conclusive.

---

*Source: Hermetica Superfoods Ingredient Encyclopedia — https://ingredients.hermeticasuperfoods.com*
*License: CC BY-NC-SA 4.0 — Attribution required. Commercial use: admin@hermeticasuperfoods.com*